


ABSTRACT OF DISCLOSURE:

A heterocyclic compound of the formula (I):



wherein B<sup>1</sup> is -C(R<sup>2</sup>)= or -N=; R<sup>1'</sup> is H, etc.; one of R<sup>1</sup> and R<sup>2</sup> is -Z<sup>1</sup>-Z<sup>2</sup>-Z<sup>3</sup>-R<sup>5</sup> wherein Z<sup>1</sup> and Z<sup>3</sup> are independently single bond, optionally substituted alkylene, etc.; Z<sup>2</sup> is single bond, optionally substituted alkylene, etc.; R<sup>5</sup> is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R<sup>1</sup> and R<sup>2</sup> is H; -A<sup>1</sup>- is -C(-Y)=C(-R<sup>A</sup>)-C(-R<sup>3</sup>)=C(-R<sup>4</sup>)-, etc. wherein Y is OH, etc.; R<sup>A</sup> is -COR<sup>7</sup> wherein R<sup>7</sup> is OH, etc.; one of R<sup>3</sup> and R<sup>4</sup> is carboxy, etc., and the other of R<sup>1</sup> and R<sup>2</sup> is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.